Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 220

Sort by

Sort Order Select

Journal Articles

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Nicole R. Grieselhuber, Praneeth Baratam, Anjali S. Advani, Abdulraheem Yacoub, Don A. Stevens, Ahmed Aribi, Ben K. Tomlinson, Jay Yang, Pankit Vachhani, Joseph G Jurcic, Caspian H. Oliai, Jessica Liegel, Edward Pearson, Anna Van Rhenen, Marcello Rotta, Kapil Rathi, Juan Pinelli, Tara Chen, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2024-199634

Published: 2024

Journal Articles

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 1): 308.

https://doi.org/10.1182/blood-2024-209438

Published: 2024

Journal Articles

Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Blood (2024) 144 (Supplement 1): 779.

https://doi.org/10.1182/blood-2024-207557

Published: 2024

Journal Articles

Outcomes of Blast-Phase MPN and JAK2 , MPL , and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2 , MPL , and CALR Genes: A Propensity Score-Adjusted Cohort Study

Blood (2024) 144 (Supplement 1): 2868.

https://doi.org/10.1182/blood-2024-207748

Published: 2024

Journal Articles

Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2024-202134

Published: 2024

Journal Articles

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Blood (2024) 144 (Supplement 1): 733.

https://doi.org/10.1182/blood-2024-209097

Published: 2024

Journal Articles

Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience

Blood (2024) 144 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2024-202525

Published: 2024

Journal Articles

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Akriti G. Jain, Joy Nakitandwe, Krishna Desai, Genevieve M Crane, David S. Bosler, Jill O'Brien, Moaath K. Mustafa Ali, John C. Molina, Sophia Balderman, Anjali S. Advani, Hetty E. Carraway, Aaron T. Gerds, Abhay Singh, Matt Kalaycio, Sudipto Mukherjee

Blood (2024) 144 (Supplement 1): 3153.

https://doi.org/10.1182/blood-2024-209165

Published: 2024

Journal Articles

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Blood (2024) 144 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2024-212146

Published: 2024

Journal Articles

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Ibrahim Muhsen, Anjali S. Advani, Gregory W Roloff, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Michael R. Grunwald, Vamsi K. Kota, Jacob Boccucci, Matthew Ulrickson, Joshua Sasine, Ibrahim Aldoss, Tamer Othman, Sumithira Vasu, Ran Reshef, Marlise R. Luskin, Evan C. Chen, Chenyu Lin, Amelia Langston, Ryan D. Cassaday, Noam E. Kopmar, Stephanie B. Tsai, Timothy E O'Connor, Talal Hilal, Rawan Faramand, Jae H. Park, Yannis K. Valtis, Melhem M. Solh, Evandro Bezerra, Jessica T. Leonard, Simone E. Dekker, Navneet Majhail, Minoo Battiwalla, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Kaitlyn C Dykes, Aaron C. Logan, Muthu V. Kumaran, Wendy Stock, Marc Schwartz, Veronika Bachanova, Sean Tracy, Kristen M. O'Dwyer, Jozal Moore, Catherine J. Lee, Maria Silvina Odstrcil Bobillo, Noelle Frey, Matthew P Connor, Omer Jamy, Michael Daunov, Abdullah Ladha, George Yaghmour, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Bhagirathbhai Dholaria, Vinod Pullarkat, Akil Merchant, Bijal D Shah, Lori Muffly, LaQuisa Hill

Blood (2024) 144 (Supplement 1): 523.

https://doi.org/10.1182/blood-2024-210682

Published: 2024

Journal Articles

Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Daniel J. Olivieri, Alexis Berridge-Green, Megan Othus, Anna B. Moseley, Jerald P. Radich, Anjali S. Advani, Harry P. Erba, Roland B. Walter

Blood (2024) 144 (Supplement 1): 2414.

https://doi.org/10.1182/blood-2024-199817

Published: 2024

Journal Articles

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

Muaz Alsabbagh Alchirazi, Hadil Zureigat, Ahmed N Mohamed, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6597.

https://doi.org/10.1182/blood-2024-206448

Published: 2024

Journal Articles

The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Blood (2024) 144 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2024-206289

Published: 2024

Journal Articles

Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

Blood (2024) 144 (Supplement 1): 6127.

https://doi.org/10.1182/blood-2024-199358

Published: 2024

Journal Articles

Evaluating Impact of Insertion Length on Clinical Outcomes in FLT3-ITD Mutated AML: A Single Center Retrospective Analysis

Blood (2024) 144 (Supplement 1): 6143.

https://doi.org/10.1182/blood-2024-209265

Published: 2024

Journal Articles

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Ahmed N Mohamed, Hadil Zureigat, Muaz Alsabbagh Alchirazi, Aastha Dhakal, Ali Mushtaq, Naveen Rehman, Bryan Berube, Sneha Govande, Emily C. Zabor, Akriti G. Jain, John C. Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Anjali S. Advani, Hetty E. Carraway, Matt Kalaycio, Sudipto Mukherjee, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 6610.

https://doi.org/10.1182/blood-2024-210152

Published: 2024

Journal Articles

Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center

Ahmed N Mohamed, Meera Patel, Hadil Zureigat, Daniel P. Nurse, Sara F Haddad, Emily C. Zabor, Yohana B. Bedelu, Mark Jinan Chen, Joy Nakitandwe, John C. Molina, Sophia Balderman, Akriti G. Jain, Abhay Singh, Sudipto Mukherjee, Aaron T. Gerds, Hetty E. Carraway, Anjali S. Advani, Moaath K. Mustafa Ali

Blood (2024) 144 (Supplement 1): 5909.

https://doi.org/10.1182/blood-2024-202558

Published: 2024

Journal Articles

BEAM-201 for the Treatment of Relapsed and/or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL): Initial Data from the Phase (Ph) 1/2 Dose-Exploration, Dose-Expansion, Safety, and Efficacy Study of Multiplex Base-Edited Allogeneic Anti-CD7 CAR-T-Cells

Caroline Diorio, Paul Shaughnessy, Nosha Farhadfar, Anjali S. Advani, Wen-Kai Weng, Hagop Youssoufian, Guo Chen, Felicia Nguyen Brown, Bahru Habtermariam, Lalit Kumar, Jigar Patel, Shangbin (Gary) Liu, Sunita Goyal, Amy Simon, Alex C. Minella, David T. Teachey

Blood (2024) 144 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2024-203546

Published: 2024

Journal Articles

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood (2024) 144 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2024-205812

Published: 2024

Journal Articles

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Yannis K. Valtis, David Nemirovsky, Sean M. Devlin, Gregory W Roloff, Ibrahim Aldoss, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Anjali S. Advani, Marlise R. Luskin, Evan C. Chen, Omer Jamy, Michael R. Grunwald, Ibrahim Muhsen, Noam E. Kopmar, Bhagirathbhai Dholaria, Simone E. Dekker, Jessica T. Leonard, George Yaghmour, Stephanie B. Tsai, Wendy Stock, Jozal Moore, Kristen M. O'Dwyer, Aaron C. Logan, Matthew P Connor, Noelle Frey, Evandro Bezerra, Sumithira Vasu, Kaitlyn C Dykes, Minoo Battiwalla, Chenyu Lin, Matthew Ulrickson, Ran Reshef, Ryan D. Cassaday, Laquisha C. Hill, Catherine J. Lee, Vamsi K. Kota, Jacob Boccucci, Joshua Sasine, Akil Merchant, Vinod Pullarkat, Amelia Langston, Talal Hilal, Rawan Faramand, Melhem M. Solh, Tamer Othman, Timothy E O'Connor, Navneet Majhail, Shabaz Malik, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Muthu V. Kumaran, Marc Schwartz, Veronika Bachanova, Sean I. Tracy, Maria Odstrcil Bobillo, Abdullah Ladha, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Michael Daunov, John Mathews, Paul Shaughnessy, Bijal D Shah, Lori Muffly, Jae H. Park

Blood (2024) 144 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2024-201610

Published: 2024

NARROW

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Addition of Inotuzumab to a Pediatric Inspired Chemotherapy Regimen in Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia: Findings from the Alliance A041501 Phase 3 Randomized Trial

Outcomes of Blast-Phase MPN and JAK2 , MPL , and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2 , MPL , and CALR Genes: A Propensity Score-Adjusted Cohort Study

Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study

Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience

Impact of Non- ABL1 Mutations on Outcomes in Patients with Chronic Myeloid Leukemia

Cardiovascular Profile of Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia: A 16-Year Observational Study

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Consent to Future Use of Residual and Banked Specimens Among Adults with Hematologic Malignancies: Analyzing SWOG Clinical Trial Data from 2000-2024

Outcomes of Second-Line Tyrosine Kinase Inhibitors after First-Line Imatinib in Chronic Myelogenous Leukemia: A Retrospective Cohort Study

The Prognostic Significance of Chromosome 17 Addition Vs. Complete and Partial Loss in Patients with Acute Myeloid Leukemia, a Single Center Experience

Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

Evaluating Impact of Insertion Length on Clinical Outcomes in FLT3-ITD Mutated AML: A Single Center Retrospective Analysis

Outcomes of Accelerated and Blast Phase Chronic Myeloid Leukemia at a Tertiary Center

Impact of P190 and P210 BCR::ABL1 Chimeric Protein on Outcomes of Acute Lymphoblastic Leukemia at a Tertiary Center

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only